{"id":391393,"date":"2015-05-29T00:00:00","date_gmt":"2015-05-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbasmd0215-biopharma-renal-anemia\/"},"modified":"2026-04-30T11:28:20","modified_gmt":"2026-04-30T11:28:20","slug":"dbasmd0215-biopharma-renal-anemia","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbasmd0215-biopharma-renal-anemia\/","title":{"rendered":"Renal Anemia"},"content":{"rendered":"<p><i>Payer and Physician Receptivity to Oral HIF-PH Inhibitors and Other Novel Treatments: Which Emerging Drugs Excite Them?<\/i> <\/p>\n<p>Renal anemia is one of the primary complications of chronic kidney disease (CKD) and is treated with erythropoiesis-stimulating agents (ESAs) and oral\/IV iron. The market for renal anemia drugs is poised to expand owing to the growing size of the CKD non-dialysis (CKD-ND) and dialysis patient populations as well as the expected launches of novel therapies such as oral hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHis) to treat renal anemia (e.g., FibroGen\/Astellas\/AstraZeneca\u2019s roxadustat, Akebia Therapeutics\u2019 AKB-6548, GlaxoSmithKline\u2019s daprodustat) and other new renal anemia treatments. Significant clinical and commercial opportunities remain for new renal anemia therapies that can provide improved effects on increasing hemoglobin, greater safety, and\/or an improved delivery profile.<\/p>\n","protected":false},"template":"","class_list":["post-391393","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-kidney-disease","biopharma-therapy-areas-renal-anemia","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391393","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391393\/revisions"}],"predecessor-version":[{"id":394516,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391393\/revisions\/394516"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}